Version history

{
  "session_id": "sess_hypdebate_h_var_e2b5a7e7db_20260427_111653",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "content": "\n\n# Expert Assessment: GluN2B-Mediated Thalamocortical Glymphatic Tau Clearance\n\n## Druggability: Moderate-to-Low\n\nThe hypothesis proposes GRIN2B modulation as a gateway to enhanced tau clearance via glymphatic flow. While GRIN2B is a validated target with known pharmacological agents, **translational viability faces substantial barriers**.\n\n**Direct GluN2B modulators exist:**\n- Ifenprodil (historical, off-patent)\n- Ro 25-6981 (selective antagonist, research use only)\n- CERC-301/MK-8658 (Concert Therapeutics/Merck) — failed in major depression Phase II (NCT02140216)\n- Nelotanserin (Axovant) — abandoned in Lewy body dementia\n\nThe fundamental problem: global GluN2B antagonism produces dose-limiting CNS toxicity (psychotomimetic effects, dissociation). **Circuit-specific targeting remains unresolved.** Even if thalamocortical synchrony could be enhanced, off-target effects on hippocampal/cortical GluN2B signaling risk excitotoxic disruption rather than neuroprotection.\n\n## Competitive Landscape\n\n**Indirect approaches dominate:**\n| Company | Approach | Status |\n|---------|----------|--------|\n| Eli Lilly | Solanezumab (anti-Aβ, not tau) | Failed; shifted to donanemab |\n| Biogen/Ionis | BIIB080 (anti-tau ASO) | Phase Ib/IIa (NCT05316723) |\n| UCB | Prasinezumab (anti-α-syn) | Parkinson's trials |\n| Novartis | GSK-3β inhibitors | Preclinical/failed |\n\n**Glymphatic enhancement strategies** (sleep optimization, ADH manipulation, perivascular targeting) are earlier stage but avoid excitotoxicity concerns entirely.\n\n## Key Feasibility Concerns\n\n1. **Glymphatic reproducibility** — Human imaging data remain inconclusive; animal models don't fully translate\n2. **Thalamus as \"glymphatic hub\"** — Mechanistic evidence is associative, not causal\n3. **Tau bidirectional relationship** — Whether enhancing clearance meaningfully alters clinical trajectory is unproven\n\n## Verdict\n\nWhile mechanistically intriguing, this hypothesis overstates control at each causal step. A more pragmatic approach would target sleep architecture directly (orexin antagonists, e.g., suvorexant) to enhance slow-wave-dependent glymphatic activity, avoiding GRIN2B's narrow therapeutic window. Cost: ~$2B and 10+ years to validate the full pathway clinically."
}